Pfizer Inc.

11/8/2026

Pfizer And 2 More AI Healthcare Stocks To Watch

The recent $3.2tn sell-off in AI related assets after the US midterm elections showed how quickly sentiment can flip when investors worry about slower AI spending and tighter rules. That kind of reset often leaves strong businesses trading on fear rather than fundamentals. This piece looks at advanced AI in healthcare and highlights three screen-selected stocks that could help you focus on this long-term shift with more discipline. The three stocks below are just a starting sample. The full...

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.

What Is Behind The Rise In Moderna Stock?

For questions about this article or underlying research, email help@trefis.com.

Xeris Biopharma (XERS) Adds Menassie M. Taddese To Its Board

Xeris Biopharma Holdings (NasdaqGS:XERS) has appointed Menassie M. Taddese to its Board of Directors. Taddese brings nearly 30 years of global biopharma experience, including senior roles at Viatris and Pfizer. His background spans commercial operations, business transformation, and financial oversight across multiple international markets. The new Board appointment of Menassie M. Taddese is only part of Xeris Biopharma's wider investment story. Our analysis turns up 1 warning sign for Xeris...

What Could Stall AbbVie Stock's Run?

For questions about this article or underlying research, email help@trefis.com.

Pfizer vs. AbbVie: Higher Yield and Cheaper Valuation Give One the Clear Edge

Pfizer offers a higher dividend yield and a cheaper valuation, while AbbVie brings stronger earnings momentum and a history of dividend growth.

Pfizer (PFE) Maps Out $650 Million Connecticut Center For Global Clinical Trials

Pfizer (NYSE:PFE) plans to build a US$650 million manufacturing technology center in Connecticut to support global clinical trials. The planned facility is expected to produce clinical active pharmaceutical ingredients and drug products for Pfizer's development pipeline. Pfizer describes the project as a long term expansion of its R&D and supply chain capabilities tied to future portfolio needs. This planned US$650 million Connecticut manufacturing technology center is a key development to...

Better Dividend Stock: Verizon vs. Pfizer

Key TakeawaysVerizon fell 9% on Oct. 9 after SpaceX agreed to buy nationwide wireless spectrum, and it now yields 6.

Better Dividend Stock for Retirees: Pfizer vs. PepsiCo

Key TakeawaysPfizer yields 5. 7% and PepsiCo yields 4.